We investigated the mechanism by which granulocyte-macrophage colony-stimulating factor (GM-CSF) lowers plasma cholesterol levels. Recombinant human GM-CSF (rhGM-CSF) was administered to normal and Watanabe heritable hyperlipidemic (WHHL) rabbits. Treatment with rhGM-CSF reduced the levels of cholesterol and triglyceride in these animals. In vitro colony assay for hematopoietic progenitors indicated that rhGM-CSF was capable of supporting granulocyte-macrophage colony formation in rabbits, suggesting that rhGM-CSF stimulates macrophage function even in rabbits. Northern blot analysis of rabbit very-low-density lipoprotein (VLDL) receptor showed that rhGM-CSF elevated the levels of VLDL receptor mRNA 2.6-and 1.8-fold in muscles of normal and WHHL rabbits, respectively, 1.5 hours after a single injection. Increases of 1.5-and 1.4-fold were observed in muscles of these rabbits after 5 days of administration.
Human granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to reduce cholesterol levels in humans (1) although this molecule was originally found to promote the proliferation and maturation of granulocytic and monocytic lineages in vitro and in vivo (2, 3) . This finding suggests that GM-CSF may play an important role in lipid metabolism. However, the mechanism(s) by which GM-CSF lowers plasma cholesterol levels is not well understood.
Macrophage colony-stimulating factor (M-CSF) promotes the proliferation and differentiation of monocytic lineage and enhances the functions of the mature cells (4) . In addition, this cytokine also lowers plasma cholesterol levels in animals and humans, the mechanisms of which have been investigated extensively (5-10).
Our in vivo experiment showed that the cholesterol-lowering effect of recombinant human GM-CSF (rhGM-CSF, Hoechst Japan Co Ltd., Tokyo, 11) persisted in normal and cholesterol-fed rabbits even after cessation of the treatment (12). Conversely, Shimano et al. reported that plasma cholesterol levels normalized in normal and Watanabe heritable hyperlipidemic (WHHL, 13) rabbits soon after cessation of M-CSF administration (6). Moreover, rhGM-CSF reduced the levels of triglyceride in rabbits, whereas M-CSF did not. According to the different modes of the biological actions of the two molecules, we hypothesized that the effects of these cytokines on the metabolism of lipoprotein might be mediated via different pathways.
In this study, we found distinct effects of GM-CSF and M-CSF on the levels of mRNA for lipoprotein receptors in individual organs in rabbits.
Actions of GM-CSF on Mature Hematopoietic
Cells and Their Progenitors rhGM-CSF administration to rabbits did not induce the reduced total cholesterol levels, but not either triglyceride or HDL-C levels in WHHL rabbits (12). Although the total doses used and the duration of the treatment were different between normal and WHHL rabbits, the major reason why rhGM-CSF administration did not significantly change the levels of triglycerides may be due to a defect in the LDL receptor in WHHL rabbits. This animal model shows the decreased uptake of VLDL and IDL by the liver and clears VLDL and intermediate-density lipoprotein (IDL) from plasma at a markedly delayed rate, giving rise to extremely high levels of LDL-C and triglyceride (15) (16) (17) . Thus, the accumulation of triglycerides was not significantly altered by rhGM-CSF in WHHL rabbits, although the VLDL receptor mRNA levels were increased in these animals by treatment with rhGM-CSF as described below.
LDL and VLDL Receptor mRNA Levels
The rabbit VLDL receptor was molecularly cloned by Takahashi et al. in 1992 (18) . Comparison of the amino acid sequence of rabbit VLDL receptor with that of the rabbit LDL receptor shows striking homology and extensive structural similarity. A critical difference in the mature protein structure between the two receptors is the number of cysteinerich repeat sequences at the N terminus (15, 18) . However, these two lipoprotein receptors have distinct ligand specificities and tissue distributions. The VLDL receptor binds apolipoprotein E (apoE)-containing lipoproteins enriched with triglyceride and its mRNA is abundant in muscle, heart and adipose tissue with little expression in liver. In addition, the human VLDL receptor gene is located on chromosome 9, whereas the human LDL receptor gene is on chromosome 19 (19) . These findings suggest that the VLDL receptor plays an important role in the metabolism of apoEcontaining lipoproteins enriched with triglyceride and that lipoprotein metabolism is regulated by at least three receptors including LDL receptor, remnant receptor and VLDL receptor.
To determine the mechanism(s) by which GM-CSF lowers cholesterol levels, we examined the effects of rhGM-CSF on the levels of LDL and VLDL receptor mRNAs by Northern blot analysis. rhGM-CSF or human urinary M-CSF (HuM-CSF, the Morinaga Milk Industry Co., Tokyo) was injected into normal and WHHL rabbits, whereas an equal amount of human serum albumin (HSA) was used in controls. The organs from rabbits treated with rhGM-CSF, HuM-CSF or HSA were removed 1.5 hours after the single injection and the 5-day administration, followed by isolation of RNA. In rabbits treated with the single injection, an increased was found in the levels of VLDL receptor mRNA in muscle (2.6-fold increase in normal rabbits), but not in the levels of LDL receptor mRNA in liver, spleen or bone marrow. In contrast, the VLDL mRNA levels were not significantly changed in muscle by treatment with HuM-CSF (12). Figure 1 shows a 1.8-fold increase in the levels of VLDL receptor mRNA in the muscle of WHHL rabbits 1.5 hours after the single injection of Table 1 . CFU-GM-derived colony formation by rhGM-CSF.
rhGM-CSF. There were 1.5-and 1.4-fold increases following the 5-day treatment in normal and WHHL rabbits (data not shown), while no changes in the LDL receptor mRNA levels were observed in liver, spleen or bone marrow (Fig. 2) . On the other hand, Shimano et al. reported increases in LDL receptor mRNA levels in spleen and bone morrow , but not in liver of rabbits treated with rhM-CSF (6). Table 2 summarizes the effects of human GM-CSF and M-CSF on VLDL and LDL receptor mRNA levels in rabbits.
Mechanisms of the Lowering of Triglyceride Levels
Treatment with rhGM-CSF lowered not only cholesterol but also triglyceride levels. The increased uptake of apoEcontaining lipoproteins enriched with triglyceride by the upregulation of VLDL receptor may partially explain the lowering of triglyceride levels by GM-CSF.
Moreover, long-chain acyl-CoA synthetase catalyzes the initial reaction in fatty acid metabolism and this enzyme is primarily distributect in liver, heart and adipose tissue (20) . Our preliminary experiment demonstrated that rhGM-CSF decreased the levels of acyl-CoA synthetase mRNA as determined by Northern blot analysis with rat long-chain acyl-CoA synthetase cDNA, suggesting that this may be one of the mechanisms responsible for the reduction in triglyceride levels. Further studies are necessary to clarify the role of this enzyme in the effects of treatment with GM-CSF.
Conclusions
Lowering of plasma cholesterol and triglyceride levels was induced by the in vivo treatment of rhGM-CSF in normal, cholesterol-fed and WHHL rabbits. We attempted to determine the mechanism(s) and showed that the cholesterollowering effect may be mediated through the enhancement of macrophage function and the up-regulation of VLDL receptor mRNA expression in muscle. Our findings also demonstrated distinct effects of GM-CSF and M-CSF on the levels of mRNA for LDL and VLDL receptors. The role of the VLDL receptor in the metabolism of triglyceride-rich lipoproteins in muscle, heart and adipose tissue remains to be elucidated. Table 2 . Effects of human GM-CSF and M-CSF on the levels of VLDL and LDL receptor mRNAs in rabbits.
